Tag: pharma policy

How to Model Policy Changes & Regulatory Impact for Global Study Portfolios

Posted on By digi

How to Model Policy Changes & Regulatory Impact for Global Study Portfolios How to Model Policy Changes & Regulatory Impact for Global Study Portfolios As the landscape of clinical research continues to evolve, professionals in clinical operations, regulatory affairs, and medical affairs must be equipped to navigate the complexities surrounding policy changes and regulatory impacts….

Read More “How to Model Policy Changes & Regulatory Impact for Global Study Portfolios” »

Policy Changes & Regulatory Impact

Policy Changes & Regulatory Impact in Practice: Benchmarks, Case Studies and Playbooks

Posted on By digi

Policy Changes & Regulatory Impact in Practice: Benchmarks, Case Studies and Playbooks Policy Changes & Regulatory Impact in Practice: Benchmarks, Case Studies and Playbooks Understanding the Landscape of Clinical Trial Regulation In the complex world of clinical research, understanding the evolving landscape of regulations is imperative for successful navigation. Regulatory bodies such as the FDA,…

Read More “Policy Changes & Regulatory Impact in Practice: Benchmarks, Case Studies and Playbooks” »

Policy Changes & Regulatory Impact

High-Impact Policy Changes & Regulatory Impact Strategies That Protect Trial Timelines and Margins

Posted on By digi

High-Impact Policy Changes & Regulatory Impact Strategies That Protect Trial Timelines and Margins High-Impact Policy Changes & Regulatory Impact Strategies That Protect Trial Timelines and Margins The landscape of clinical research has evolved significantly over the past decade, influenced by rapid advancements in technology, changing regulatory environments, and shifts in patient-centricity. This tutorial provides a…

Read More “High-Impact Policy Changes & Regulatory Impact Strategies That Protect Trial Timelines and Margins” »

Policy Changes & Regulatory Impact

Linking Policy Changes & Regulatory Impact to Market Access, HTA and Payer Expectations

Posted on By digi

Linking Policy Changes & Regulatory Impact to Market Access, HTA and Payer Expectations Linking Policy Changes & Regulatory Impact to Market Access, HTA and Payer Expectations The landscape of clinical research is continuously evolving, driven by changes in regulatory frameworks, health technology assessment (HTA) processes, and payer expectations. As professionals involved in clinical operations, regulatory…

Read More “Linking Policy Changes & Regulatory Impact to Market Access, HTA and Payer Expectations” »

Policy Changes & Regulatory Impact

KPIs, Dashboards and Scorecards to Track Pricing, Reimbursement & HTA Interfaces

Posted on By digi

KPIs, Dashboards and Scorecards to Track Pricing, Reimbursement & HTA Interfaces KPIs, Dashboards and Scorecards to Track Pricing, Reimbursement & HTA Interfaces In today’s complex clinical research environment, characterized by regulatory frameworks such as ICH-GCP, FDA, EMA, and MHRA guidelines, the need for effective monitoring of key performance indicators (KPIs), dashboards, and scorecards is paramount….

Read More “KPIs, Dashboards and Scorecards to Track Pricing, Reimbursement & HTA Interfaces” »

Pricing, Reimbursement & HTA Interfaces

Vendor, Site and Partner Negotiation Tactics Driven by Pricing, Reimbursement & HTA Interfaces

Posted on By digi

Vendor, Site and Partner Negotiation Tactics Driven by Pricing, Reimbursement & HTA Interfaces Effective Vendor, Site and Partner Negotiation Tactics in Clinical Trials The landscape of clinical trials continues to evolve, particularly with the increasing emphasis on remote monitoring in clinical trials and cost management strategies. As operational complexities rise, clinical operations, regulatory affairs, and…

Read More “Vendor, Site and Partner Negotiation Tactics Driven by Pricing, Reimbursement & HTA Interfaces” »

Pricing, Reimbursement & HTA Interfaces

Scenario Planning: Best-Case and Worst-Case Pricing, Reimbursement & HTA Interfaces Outlooks

Posted on By digi

Scenario Planning: Best-Case and Worst-Case Pricing, Reimbursement & HTA Interfaces Outlooks Best-Case and Worst-Case Pricing, Reimbursement & HTA Interfaces Outlooks in Clinical Trials In the rapidly evolving landscape of clinical trials, effective scenario planning is essential for anticipating and preparing for potential pricing, reimbursement, and Health Technology Assessment (HTA) outcomes. This comprehensive guide serves as…

Read More “Scenario Planning: Best-Case and Worst-Case Pricing, Reimbursement & HTA Interfaces Outlooks” »

Pricing, Reimbursement & HTA Interfaces

Investor, Board and C-Suite Questions Around Pricing, Reimbursement & HTA Interfaces—Answered

Posted on By digi

Investor, Board and C-Suite Questions Around Pricing, Reimbursement & HTA Interfaces—Answered In the evolving landscape of clinical trials, particularly those involving paid virtual clinical trials, it is crucial for biopharmaceutical executives to have a solid grasp of pricing, reimbursement, and health technology assessment (HTA) interfaces. This article provides a step-by-step tutorial aimed at addressing comprehensive…

Read More “Investor, Board and C-Suite Questions Around Pricing, Reimbursement & HTA Interfaces—Answered” »

Pricing, Reimbursement & HTA Interfaces

Future Trends: AI, RWE and New Business Models in Pricing, Reimbursement & HTA Interfaces

Posted on By digi

Future Trends in Clinical Trials: AI, RWE and New Business Models in Pricing, Reimbursement & HTA Interfaces The evolution of clinical trials is undergoing profound changes driven by innovative technologies and methodologies. Among these, Artificial Intelligence (AI) and Real-World Evidence (RWE) are emerging as pivotal elements influencing pricing, reimbursement, and Health Technology Assessment (HTA) processes….

Read More “Future Trends: AI, RWE and New Business Models in Pricing, Reimbursement & HTA Interfaces” »

Pricing, Reimbursement & HTA Interfaces

Digital Tools and Analytics to Forecast and Monitor Pricing, Reimbursement & HTA Interfaces

Posted on By digi

Digital Tools and Analytics to Forecast and Monitor Pricing, Reimbursement & HTA Interfaces Digital Tools and Analytics to Forecast and Monitor Pricing, Reimbursement & HTA Interfaces Introduction to Digital Tools and Analytics in Clinical Trials The integration of digital tools into clinical trials is revolutionizing the way researchers forecast and monitor various essential components such…

Read More “Digital Tools and Analytics to Forecast and Monitor Pricing, Reimbursement & HTA Interfaces” »

Pricing, Reimbursement & HTA Interfaces